# Presentation: 316340

## The Biotechnology Industry Organization(BIO)Washington, DCNew York, NYSan Francisco & San Diego, CA

## What is BIO?

***BIO*** Is The World’s Largest Biotechnology Industry Association
- Established In 1993
- 1,000+ Members In All US States & 35 Nations
- 80+ Staff Members
- Headquartered In Washington, DC, With An Office In New York & Representatives In San Francisco And San Diego

## BIO’s Membership Includes:

- 15 of the top 16 Big Pharma
- 96 of the top Public Biotech Companies
- Private Companies
- Industry Suppliers
- Professional Service Providers
- Academic Research Institutions
- Biotech Centers
- Government Agencies

## BIO’s Staff Concentrates On:

- Government Relations
- Reimbursement
- Intellectual Property
- Bioethics
- Regulatory Affairs
- Industrial & Environmental
- Food and Agriculture
- Communications
- Business Development & Investor Relations

## BIO’s Major Advocacy Agenda

- Reimbursement
- Intellectual Property Protection
- Bioethics Issues
- Food & Agriculture
- Industrial Biotechnology
- Tax Policy (Monetizing Earned Credits)
- Homeland Security Issues (BioShield)
- Regulatory Agencies  (FDA, USDA, EPA)

## BIO’s Major Legislative Accomplishments 

- PDUFA III
- Stop Loss Coverage In All Draft Medicare Legislation
- No Legislative Ban On Therapeutic Cloning
- Enacted Legislation That Prohibits Health Insurers From Using Genetic Information To Deny Coverage
- Kennedy-Frist Anti-Bioterrorism bill

## Leveraging BIO’s Assets

- Broad Support For Industry On Capital Hill
***BIO*** is not PhRMA
- Grassroots – Members in all 50 States
***BIO*** Political Action Committee
- Close to Most Patient Groups

## State Activities In Biotech:

- States more active and involved in biosciences than at any time in the past decade
- Factors contributing to this rising interest include:
- Public attention to human genomics
- Tobacco Settlement funds
- Demise of the dot.com industry
- Public interest in human health & disease prevention

## How States Support The Biotech Industry

- Using Tobacco Settlement Funds For Biotech
- Increased State Government Funding Of Academic Biotech Research Centers
- Focus On Financing Needs Of Biotech Companies
- Financing Facilities For Biotech Companies
- Growth of State Biotech Trade Associations & Networks

- Source:  Battelle Memorial Institute

## What The States Are Doing To Support The Biotech Industry (Cont’d)

- High Priority Given to Regulatory & Tax Issues
- Increasing Interest In Developing Biotech-related Research Parks & Incubators
- Emergence Of Bioscience Commercialization & Business Development Initiatives
- Increased Attention To Workforce Training & Development Programs

- Source:  Battelle Memorial Institute

## Recipe for Cluster Success

- Engaged Universities With Active Leadership
- Available Capital
- Discretionary funding (federal/state) for R&D
- Workforce & Talent Pool
- Access to specialized facilities and equipment
- Patience and long-term perspective
- Entrepreneurial culture
- Supportive regulatory and fiscal environment

- Source:  Battelle Memorial Institute

## BIO’s Investor Relations & Business Development Programs

**Investor Relations**
**Business Development**
**Training**

## BIO’s Investor Relations Programs

*BIO* CEO & Investor Conference
*BIO*-Equity
*BIO*-VentureForum East
*BIO*-VentureForum West
*BIO* Mid-America

## BIO’s Business Development Programs

*BIO*’s Annual Meeting, Business Forum
*BIO*-Partnering Europe
*BIO*-Nordic
*BIO*-Windhover
*BIO*-Square
*BIO* AsiaPacific

## BIO’s Information & Training Programs

- Investor Briefings
- Sell-side Briefings
- Road Shows
- Effective Presentation Techniques
- Business Development For Biotech Executives

## BIO Membership Privileges

- Access To Industry Leaders In The Biotech & Pharma Industries
- Access To *BIO*’s Business Development & Investor Markets *BIO*-Organized Events
- Play A Role In Development Of Legislative & Regulatory Policies
- Access To Group Purchasing Program

## How To Contact BIO

**www.bio.org **
- Patrick Kelly, Vice President, State Government Relations, BIO, Washington, DC, Tel:  202 962- 9200, e-mail: _[pkelly@bio.org](mailto:pkelly@bio.org)_
- Sara Jane Demy, Director, Investor Relations & Business Development, BIO, New York, NY, Tel: 212 292-5500, e-mail: _[sdemy@bio.org](mailto:sdemy@bio.org)_